Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 2.76% | 22.52% | |||
| Gross Profit | -2.76% | -39.64% | |||
| SG&A Expenses | 0.20% | 1.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.24% | 17.44% | |||
| Operating Income | -2.24% | -29.55% | |||
| Income Before Tax | -5.73% | -32.05% | |||
| Income Tax Expenses | 208.15% | -246.60% | |||
| Earnings from Continuing Operations | -7.31% | -30.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.31% | -30.22% | |||
| EBIT | -2.24% | -29.55% | |||
| EBITDA | -2.24% | -29.85% | |||
| EPS Basic | -6.91% | -29.80% | |||
| Normalized Basic EPS | -5.33% | -31.60% | |||
| EPS Diluted | -6.91% | -29.80% | |||
| Normalized Diluted EPS | -5.33% | -31.60% | |||
| Average Basic Shares Outstanding | 0.37% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.37% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||